한국어
미제공
과학 프로그램 1 일 차
English
한국어
미제공
Explore the Agenda
일정 확인하기
7:45 am Check-In & Morning Coffee
8:45 am Program Director’s Opening Remarks
8:50 am Chair’s Opening Remarks
Progressing ADC Innovation in South Korea to Overcome Competition & Be Best-in-Class in a Crowded Market
9:00 am Panel Discussion: Hearing Korean ADC Developers’ Perspectives on ADC Development to Accelerate Innovation & Establish South Korea as a Hub of ADC Development
- Honing insights from ADC pioneers in South Korea on cutting-edge research and lessons learned that are driving innovations
- Understanding how partnerships with pharma are accelerating ADC development
- Analyzing the future direction of ADC development to strengthen Korea’s global leadership in next-generation ADC therapeutics
9:45 am Reviewing the Performance of the Tubulis Tubutecan Technology From Clinic to CMC to Understand Its Advantages in Improving Stability
- Exploring the superiority of the Tubutecan technology from the standpoints of quality attributes and stability
- Sharing recent clinical data from the Tubutecan technology
- Discussing technology development across scales toward late-stage development
10:15 am Refreshment Break
10:45 am Networking
This is your opportunity to have face-to-face conversations with fellow attendees of the World Targeted Therapeutics Summit South Korea by Hanson Wade. Progress your ADC candidates forward and make connections with global pharma and biotech working on ADCs, targeted protein degradation, induced proximity, bispecifics, and T-Cell engagers, as well as global service providers, in a mix of pre-organized and ad-hoc networking.
Discovery Track
Exploring Novel Payloads Such as Radioactive Isotopes, Non-MMAE & Degraders Payloads to Stand-Out From the Saturated Market & Ensure Your ADC is First-in-Class
11:30 am Pioneering Novel ADC Payloads: Validating Proteasome Inhibitors as a First-in-Class Mechanistic Strategy
Associate Director, Qurient
- Addressing unmet needs in the current ADC landscape by highlighting the limitations of existing payload classes and the growing necessity for new mechanisms of action
- Introducing the QLi5 proteasome inhibitor platform to demonstrate how non-traditional ADC payloads can be validated and advanced into viable ADC payload strategies
- Discussing how innovative payload mechanisms can broaden the payload landscape for next-generation ADCs
12:00 pm Modeling ADC Payload Biology Using Simulated Cells
- Presenting a cell signaling network-based computational model of cytotoxic payload response across diverse molecular contexts
- Showcasing predicted response results from test samples across cancer subtypes, including examples with SLFN11 and SN38- Prexasertib
- Demonstrating the value of cell simulations to predict drug perturbations and reveal mechanistic insights to guide ADC discovery
Session Reserved for Turbine
12:30 pm ADC Payload Discovery: Themes, Strategies & Challenges for the Next Generation of ADCs
Senior Director ADC Chemistry, Pfizer
- Understanding the importance of new chemotypes for advancing the clinical impact of the ADC modality
- Discussing event-driven pharmacology as a guiding theme for new payload discovery
- Outlining strategic considerations for mechanism of action of new payloads
Preclinical & Clinical Track
CMC Track
1:30 pm Lunch
1:45 pm Networking Session
This is your opportunity to have face-to-face conversations with fellow attendees of the World Targeted Therapeutics Summit South Korea by Hanson Wade. Progress your ADC candidates forward and make connections with global pharma and biotech working on ADCs, targeted protein degradation, induced proximity, bispecifics, and T-Cell engagers, as well as global service providers, in a mix of pre-organized and random networking.
Discovery Track
Identifying Next-Generation Conjugation Technologies to Improve Tumor Targeting, ADC Stability & Accurately Inform ADC Development
2:30 pm Degrader-Antibody Conjugates: The Next Generation of ADCs
Chief Executive Officer, RealizeEdge
- Overviewing principles of targeted protein degraders to improve specificity of tumor-cell killing
- Explore the advantages of TPDs as therapeutic payloads
- Assessing the applications for degrader-antibody conjugates in oncology and immunology as the future of precise targeting
3:00 pm Session Reserved for Biocytogen
3:30 pm Examining Photomedicine ADCs: Spatial & Temporal Photo-Activation
Professor & Faculty Fellow, Northeastern University
- Overview of the advantages of photomedicine
- Explore photo-cleavable linkers for spatial and temporal activation
- Related topic on photodynamic therapy (PDT), i.e., photosensitizer-antibody conjugate (PAC)
Preclinical & Clinical Track
CMC Track
4:00 pm Refreshment Break & Scientific Poster Session
Enjoy the opportunity to share your research and discuss your peers latest data through during the Scientific Poster Session.
Advancing ADC Development Strategies From Enhanced Conjugation Approaches to Novel Linker-Payload Technologies to Improve Tumor Delivery & Therapeutic Efficacy
Advancing ADC Development Strategies From Enhanced Conjugation Approaches to Novel Linker-Payload Technologies to Improve Tumor Delivery & Therapeutic Efficacy
5:00 pm Defining How ADC Payloads Enhance Tumor Immunogenicity & Unlock Transformative Benefit With Immunotherapy
- Examining clinical ADC combinations with immunotherapy
- Differentiating ADC payloads by tumor-intrinsic immunogenic cell death (ICD) and activity on immune cells
- Assessing evidence of vedotin ADC immunogenicity in patients
5:30 pm From IND to Long-Term Commercial Supply: A Step Ahead Against the Challenges of Bioconjugates
- Explore how innovators can be served from the candidate selection to the IND, from phase I to the long-term commercial supply
- Highlight the approach to support early-stage program through robust development studies
- Overview conjugation and fill/finish capabilities
- Deliver important updates on conjugation and fill-finish capacity
6:00 pm Bridging Two Modalities: Explore How Dual-Precision Targeted Protein Degradation (TPD2) Enables Cell-Specific GSPT1 Degradation for Potent Antitumor Activity
- Discover how Orum’s TPD² platform fuses antibody targeting with catalytic protein degradation to deliver potent activity against undruggable intracellular targets
- Discuss ORM-1153, a CD123-targeting Degrader Antibody Conjugate (DAC) with a novel GSPT1-degrading payload, with the aim of achieving selective delivery to AML blasts and inducing cytotoxicity via GSPT1 degradation
- Outline the proprietary linker technology used to enable the stable conjugation and subsequent traceless, intracellular release of the TPD payloads from the antibody
6:30 pm WuXi XDC: Technology Innovation & Global Expansion to Empower Bioconjugate Development From Concept to Commercialization
- Exploring the WuXiDAR4 novel conjugation technology and payload linker platform to enable development of better ADCs with increased stability and a wider therapeutic index
- Spotlighting the WuXi XDC Singapore site: The cornerstone of global dual sourcing strategy
- Highlighting integrated CRDMO solutions to empower bioconjugate development from concept to commercialization